Advertisement

International Journal of Hematology

, Volume 80, Issue 2, pp 190–192 | Cite as

Successful Allogeneic Bone Marrow Transplantation in a Patient with Acute Myelogenous Leukemia and Cytomegalovirus Retinitis

  • Hiroshi Matsubara
  • Souichi Adachi
  • Jun Yano
  • Noriko Kitamura
  • Maki Miyazaki
  • Yasuhiro Mizushima
  • Hidefumi Hiramatsu
  • Michihiro Kobayashi
  • Tatsutoshi Nakahata
Case Report

Abstract

A 1-year-old boy with acute myeloid leukemia with cytomegalovirus (CMV) retinitis that was refractory because of severely impaired cellular immunity underwent bone marrow transplantation from an HLA-matched donor after a conditioning regimen of busulfan, cyclophosphamide, and etoposide. Although we continued administration of ganciclovir from preparation therapy, retinitis worsened after engraftment. Thereafter retinitis improved gradually as the number of CD4+ T-lymphocytes increased.The findings in this case suggest that stem cell transplantation for a leukemia patient with CMV disease may be effective.

Key words

CMV antigenemia Cellular immunity CMV seropositive Immunosuppression Stem cell transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood. 1991;78:1373–1380.PubMedGoogle Scholar
  2. 2.
    Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111–1116.CrossRefPubMedGoogle Scholar
  3. 3.
    Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–1979.PubMedGoogle Scholar
  4. 4.
    Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood. 2001;98:1358–1364.CrossRefPubMedGoogle Scholar
  5. 5.
    Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038–1044.CrossRefPubMedGoogle Scholar
  6. 6.
    Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916–3922.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaneko M, Watanabe T, Watanabe H, et al. Successful unrelated cord blood transplantation in an infant with Wiskott-Aldrich syndrome following recurrent cytomegalovirus disease. Int J Hematol. 2003;78:457–460.CrossRefPubMedGoogle Scholar
  8. 8.
    Tazume K, Hagihara M, Gansuvd B, et al. Induction of cytomegalovirus-specific CD4+ cytotoxic T lymphocytes from seropositive or negative healthy subjects or stem cell transplant recipients. Exp Hematol. 2004;32:95–103.CrossRefPubMedGoogle Scholar
  9. 9.
    Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBVspecific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002;168:909–918.CrossRefPubMedGoogle Scholar
  10. 10.
    Lucas KG, Sun Q, Burton RL, et al. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther. 2000;11:1453–1463.CrossRefPubMedGoogle Scholar
  11. 11.
    Tomonari A, Iseki T, Ooi J, et al. Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan. Br J Haematol. 2003;121:304–311.CrossRefPubMedGoogle Scholar
  12. 12.
    Erice A, Borrell N, Li W, Miller WJ, Balfour HH Jr. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J Infect Dis. 1998;178:531–534.CrossRefPubMedGoogle Scholar
  13. 13.
    Limaye AP, Corey L,Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–649.CrossRefPubMedGoogle Scholar
  14. 14.
    Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis. 1997;176:786–789.CrossRefPubMedGoogle Scholar
  15. 15.
    Jabs DA, Enger C,Forman M, Dunn JP. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42:2240–2244..PubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Hiroshi Matsubara
    • 1
    • 2
  • Souichi Adachi
    • 1
  • Jun Yano
    • 1
  • Noriko Kitamura
    • 1
  • Maki Miyazaki
    • 1
  • Yasuhiro Mizushima
    • 1
  • Hidefumi Hiramatsu
    • 1
  • Michihiro Kobayashi
    • 1
  • Tatsutoshi Nakahata
    • 1
  1. 1.Department of PediatricsKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Department of PediatricsGraduate School of Medicine, Kyoto UniversityJapan

Personalised recommendations